EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Global and Temporal Trends in Utilization and Outcomes of Implantable Cardioverter Defibrillators in Hypertrophic Cardiomyopathy

Omar M Abdelfattah iD, Ahmed Sayed iD, Ahmed Al-Jwaid iD, Ahmed Hassan iD, Deaa Abu Jazar, Arun Narayanan iD, Mark S Link iD, Matthew W Martinez iD

Circulation: Arrhythmia and Electrophysiology · 2025

DOI: 10.1161/circep.124.013479 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Circulation: Arrhythmia and Electrophysiology, 2025. Verfasst von Omar M Abdelfattah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hypertrophic Cardiomyopathy Center, Division of Cardiovascular Medicine, University of Texas Medical Branch, Galveston (O.M.A., D.A.J., A.N.). Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Defibrillators, Implantable, Death, Sudden, Cardiac, Electric Countershock. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 262 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Over the past decades, hypertrophic cardiomyopathy has become a contemporary treatable disease. However, limited data exist on the global trends of implantable cardioverter defibrillator (ICD) utilization and its impact on mortality/morbidity burden reduction. METHODS: Electronic databases were systematically searched up to March 2024 for studies reporting on ICD utilization rates in hypertrophic cardiomyopathy. A random effects model was used to pool study estimates across time-era, geographic region, and age group. Primary outcome was global trends in ICD utilization. Secondary outcomes included trends of sudden cardiac death, appropriate/inappropriate shocks, and ICD-related complications. RESULTS: In total, 234 studies (N=92 500, 514 748 patient-years) met inclusion criteria. Mean age was 46.2 (12.4) years and 37.49% were women. A total of 12 139 patients (16.43%) received an ICD over 429 766 person-years of follow-up, with an ICD implantation rate of 2.79%/y ([95% CI, 2.35%–3.32%] I²=97.80%). Rates of ICD implantation steadily increased over time from 1990 (1.09%) to 2021 (4.01%; P =0.002), with noticeable geographic variation ( P =0.008). The overall rate of appropriate ICD discharges and ICD-related complications was 3.44%/y ([95% CI, 3.08%–3.84%] I²=88.40%) and 1.98%/y ([95% CI, 1.52%–2.59%] I²=90.44%), respectively, with no significant trend over time. The overall rate of inappropriate discharges was 3.58%/y ([95% CI, 3.08%–4.16%] I 2 =88.03%), and declined significantly over time ( P =0.044). There was a significant decline in the rates of sudden cardiac death from 1990 (0.84%/y) to 2020 (0.31%/y). CONCLUSIONS: Dramatic increases in ICD utilization have occurred, representing a 3.7-fold increase, with appropriate therapies occurring in 3.44%/y. In parallel a significant reduction in sudden cardiac death was observed, but there are insufficient data to demonstrate that a causative relationship exists. Geographic disparities in ICD utilization were evident, highlighting the need to improve access to specialized care for patients with hypertrophic cardiomyopathy. Geographic disparities in ICD utilization were evident, highlighting the need to improve access to specialized care for patients with hypertrophic cardiomyopathy. REGISTRATION: URL: https://www.crd.york.ac.uk/PROSPERO/ ; Unique identifier: CRD42023407126

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicDefibrillators, ImplantableDeath, Sudden, CardiacElectric CountershockHumansFemaleMaleMiddle AgedTime FactorsTreatment OutcomeAdultGlobal HealthRisk Factors

Stichwörter der Autor:innen

cardiomyopathy, hypertrophicdeath, sudden, cardiacdefibrillators, implantablemorbiditymortality

Autor:innen und Institutionen

  • Hypertrophic Cardiomyopathy Center, Division of Cardiovascular Medicine, University of Texas Medical Branch, Galveston (O.M.A., D.A.J., A.N.).
  • Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, TX (A.S.).
  • Department of Medicine (A.A.-J.), Morristown Medical Center, Atlantic Health System, Morristown, NJ.
  • Division of Cardiology, Department of Pediatrics, The Labatt Family Heart Center, Hospital for Sick Children & University of Toronto, Ontario, Canada (A.H.).
  • Hypertrophic Cardiomyopathy Center, Gagnon Cardiovascular Institute, Department of Cardiovascular Medicine (M.S.L.), Morristown Medical Center, Atlantic Health System, Morristown, NJ.
  • Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas (M.S.L.).

ORCID-Profile: Omar M Abdelfattah, Ahmed Sayed, Ahmed Al-Jwaid, Ahmed Hassan, Arun Narayanan, Mark S Link, Matthew W Martinez

Zitieren

APA

Abdelfattah, O. M., Sayed, A., Al-Jwaid, A., Hassan, A., Abu Jazar, D., Narayanan, A., Link, M. S., & Martinez, M. W. (2025). Global and Temporal Trends in Utilization and Outcomes of Implantable Cardioverter Defibrillators in Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology. https://doi.org/10.1161/circep.124.013479

Vancouver

Abdelfattah OM, Sayed A, Al-Jwaid A, Hassan A, Abu Jazar D, Narayanan A, et al. Global and Temporal Trends in Utilization and Outcomes of Implantable Cardioverter Defibrillators in Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology. 2025. doi:10.1161/circep.124.013479

BibTeX
@article{Abdelfattah2025,
  author = {Abdelfattah, Omar M and Sayed, Ahmed and Al-Jwaid, Ahmed and Hassan, Ahmed and Abu Jazar, Deaa and Narayanan, Arun and Link, Mark S and Martinez, Matthew W},
  title = {Global and Temporal Trends in Utilization and Outcomes of Implantable Cardioverter Defibrillators in Hypertrophic Cardiomyopathy},
  journal = {Circulation: Arrhythmia and Electrophysiology},
  year = {2025},
  doi = {10.1161/circep.124.013479}
}
Kostenlos starten →